Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposome and Capecitabine in Second-line Advanced Pancreatic Cancer
NCT06578052Phase 2Recruiting
- Start
- Aug 2024
- Primary completion
- Sep 2027
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan liposome injection in pancreatic cancer (PC). Started Aug 2024; status: recruiting.
02
Drugs
irinotecan liposome injection
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06578052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06578052.